Daiichi Sankyo, AstraZeneca, and Summit Therapeutics are teaming up to test a TROP2 ADC plus a PD-1/VEGF bispecific antibody in a Phase 3 trial for aggressive breast cancer. It's a rare three-company deal that could redefine how oncology combinations are built.
The Oncology Power Play Nobody Saw Coming
When AstraZeneca dropped $2 billion on Summit Therapeutics equity just days ago, the industry took notice. Now we know what they're building toward.
Daiichi Sankyo, AstraZeneca, and Summit Therapeutics just announced a three-way clinical trial collaboration that pairs two very different cancer weapons into one regimen. The plan: combine Datroway (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate, with ivonescimab, a PD-1/VEGF bispecific antibody. The first big test? A Phase 3 trial in first-line triple-negative breast cancer, one of the most aggressive and hard-to-treat forms of the disease.
This isn't a licensing deal. It's not an acquisition. It's three companies pooling their best oncology assets into a combination that, if it works, could reshape how doctors attack solid tumors.
What's Actually in the Cocktail
Think of this combination like a two-pronged military strategy. One weapon goes after the enemy directly. The other cuts off its supply lines and reinforcements.
Datroway is an antibody-drug conjugate, or ADC. Picture a guided missile: an antibody locks onto a protein called TROP2 on the surface of cancer cells, then delivers a toxic payload directly inside. It's targeted chemotherapy, designed to kill tumor cells while (mostly) leaving healthy tissue alone. Daiichi Sankyo and AstraZeneca already have this drug approved for multiple types of breast cancer and are expanding into lung cancer.
Ivonescimab is Summit's crown jewel, a bispecific antibody that blocks two targets at once: PD-1 (an immune checkpoint that tumors exploit to hide from the immune system) and VEGF (a signal that tumors use to grow new blood vessels and feed themselves). One molecule, two jobs. It's already approved in China, making it the world's first approved anti-PD-1/VEGF bispecific antibody.
The theory is elegant. Datroway poisons the cancer cells directly. Ivonescimab wakes up the immune system starves the tumor of its blood supply. Attack, expose, suffocate.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
and
Why This Three-Way Deal Is Unusual
Pharma collaborations happen all the time, but a three-company clinical trial agreement is genuinely rare. The structure matters here.
AstraZeneca or Daiichi Sankyo will sponsor the trials. Each company contributes its own drug and shares the costs. Summit keeps full control of ivonescimab in its licensed territories (the U.S., Canada, Europe, Japan, and more). Nobody is giving up their franchise; they're testing whether the combination creates something bigger than either drug alone.
The backstory adds context. Summit licensed ivonescimab from China's Akeso in a deal worth up to $5 billion, including a $500 million upfront payment. Then AstraZeneca came in with that massive $2 billion equity investment in Summit. The clinical collaboration announced this week is the natural next step: AstraZeneca isn't just betting on Summit's stock price. It's betting that ivonescimab will make its own cancer drugs work better.
Datroway's Resume Is Already Impressive
This isn't a gamble on an unproven drug. Datroway has real data across multiple tumor types.
In HR-positive/HER2-negative metastatic breast cancer, it extended median progression-free survival to 6.9 months versus 4.9 months for chemotherapy. That's a 37% reduction in the risk of disease worsening. In metastatic triple-negative breast cancer (the exact setting for this new combo trial), the numbers were even more striking: 10.8 months versus 5.6 months for progression-free survival, nearly doubling it. Patients also lived about 5 months longer overall.
The side effect profile is manageable but not invisible. Mouth sores (stomatitis) and eye-related events are the most commonly flagged issues, consistent with the drug's mechanism.
The TROP2 ADC Wars Are Heating Up
Datroway doesn't operate in a vacuum. The TROP2-targeted ADC market has become one of oncology's most competitive arenas.
Gilead's Trodelvy (sacituzumab govitecan) was the first TROP2 ADC to market and still carries strong brand recognition in breast cancer. Merck and Kelun-Biotech's sacituzumab tirumotecan is the hungriest challenger, with multiple Phase 3 programs advancing fast. The battle is no longer about whether TROP2 ADCs work. It's about which payload, which linker chemistry, and which combination strategy wins each tumor type.
Datroway's edge? Breadth. With approvals spanning HR-positive breast cancer, triple-negative breast cancer, and expansion into non-small cell lung cancer, it has the widest label of any TROP2 ADC on the market. Adding a bispecific antibody partner could widen that moat further.
The Bigger Picture: ADC-Plus-Bispecific Is the New Frontier
Zoom out, and this trial represents something larger than any single drug combination. The oncology field is entering a new era of "rationally designed" regimens, where companies pair drugs based on complementary biology rather than just stacking whatever's available.
BioNTech is testing its own PD-L1/VEGF bispecific (pumitamig) alongside B7-H3, TROP2, and HER3 ADCs. Other companies are engineering single molecules that combine bispecific targeting with ADC payloads, cramming the whole strategy into one drug. The logic is consistent across all of these efforts: ADCs kill tumor cells; bispecifics reshape the tumor environment. Together, they might overcome resistance that either drug would hit alone.
But honesty requires a caveat. Most ADC-plus-bispecific data is still early-phase. Conference posters and Phase 1 dose-escalation results are not the same as randomized Phase 3 survival data. The Daiichi/AstraZeneca/Summit collaboration is notable precisely because it's jumping straight to Phase 3 in a meaningful patient population.
What to Watch For
The initial Phase 3 trial targeting first-line triple-negative breast cancer will be the bellwether. TNBC is a brutal disease with limited options, which means the regulatory bar for showing benefit is relatively clear: beat the current standard of care on progression-free or overall survival.
If the combination delivers, expect a rapid cascade of expansion trials across lung, gastric, and other solid tumors. If it stumbles on safety (combining two active agents always raises toxicity questions), the ripple effects could slow the entire ADC-plus-bispecific movement.
For Summit, this collaboration is validation from two of oncology's biggest players that ivonescimab belongs in the conversation. For AstraZeneca and Daiichi Sankyo, it's a calculated bet that their ADC franchise gets stronger with the right dance partner. And for patients with triple-negative breast cancer, it's another reason to hope that the next generation of cancer treatment is more than the sum of its parts.
Clinical & Regulatory
4 min read
Amgen's $28 Billion Bet on Horizon Just Got a Whole Lot Smarter
Amgen's $27.8 billion Horizon Therapeutics acquisition just delivered its biggest pipeline surprise yet. A fusion protein that blocks immune cell crosstalk passed its first pivotal trial in Sjögren's disease, a condition with zero approved treatments, and the implications for Amgen's autoimmune franchise are massive.
